Cerebral Blood Flow and Ventilatory Responses During Sleep in Normoxia and Intermittent Hypoxia

ConditionsObstructive Sleep Apnea of Adult Hypoxia, Brain Sleep Apnea Sleep Disorder Stroke Blood Pressure Endothelial Dysfunction Oxidative Stress

Trial statusRecruiting

Trial phasePhase 1, Phase 2

Trial typeInterventional

Biological sexAll

Age18-45

SponsorUniversity of Calgary

About this trial

A prospective double blind, placebo-controlled, randomized cross-over trial to evaluate the effect of lowering cerebral blood flow on the ventilatory chemoreflexes (acute hypoxic and hypercapnic ventilatory responses).

Eligibility criteria

Qualifiers

Healthy adults

18 - 45 years of age

Living in Calgary for the past one year

Have no medical condition or should not be taking any blood pressure medications.

Disqualifiers

Cerebrovascular, cardio-respiratory, renal and metabolic diseases

Bleeding disorders and upper gastrointestinal diseases e.g. peptic ulcer disease

Pregnancy, obese and sleep-disordered breathing

Drug allergies to non-steroidal anti-inflammatories

Trial design

Treatments tested in this trial

Drug Lowering Cerebral Blood Flow (CBF) and Normoxia Sleep
Drug Lowering CBF and Intermittent Hypoxia Sleep
Placebo and Normoxia Sleep
Placebo and Intermittent Hypoxia Sleep

Treatment groups

12 Participants

are divided into 4 treatment groups

Locations

University of CalgaryT2N 4N1, CalgaryAlberta, Canada

Sponsors and collaborators

University of Calgary

Lead sponsor

Source ClinicalTrials.gov